WO2007079146A8 - Treatment for non-hodgkin's lymphoma - Google Patents
Treatment for non-hodgkin's lymphomaInfo
- Publication number
- WO2007079146A8 WO2007079146A8 PCT/US2006/049431 US2006049431W WO2007079146A8 WO 2007079146 A8 WO2007079146 A8 WO 2007079146A8 US 2006049431 W US2006049431 W US 2006049431W WO 2007079146 A8 WO2007079146 A8 WO 2007079146A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hodgkin
- lymphoma
- treatment
- ameliorate
- symptom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a method of treating Non-Hodgkin's lymphoma. Generally, the method includes administering to a patient with Non-Hodgkin's lymphoma an amount of a TLR agonist compound effective to ameliorate at least one symptom or clinical sign of Non-Hodgkin's lymphoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75442405P | 2005-12-28 | 2005-12-28 | |
US60/754,424 | 2005-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007079146A1 WO2007079146A1 (en) | 2007-07-12 |
WO2007079146A8 true WO2007079146A8 (en) | 2007-08-30 |
Family
ID=38228554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/049431 WO2007079146A1 (en) | 2005-12-28 | 2006-12-28 | Treatment for non-hodgkin's lymphoma |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007079146A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106474143A (en) * | 2015-08-26 | 2017-03-08 | 长春华普生物技术有限公司 | Toll-like receptor TLR7 and TLR9 inhibition oligonucleotides are preparing for treating the application in terms of the medicine of B cell lymphoma |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004266658A1 (en) | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo-containing compounds |
KR101106812B1 (en) | 2003-08-27 | 2012-01-19 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines |
EP1660026A4 (en) | 2003-09-05 | 2008-07-16 | 3M Innovative Properties Co | Treatment for cd5+ b cell lymphoma |
JP5043435B2 (en) | 2003-10-03 | 2012-10-10 | スリーエム イノベイティブ プロパティズ カンパニー | Alkoxy substituted imidazoquinolines |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
JP2007511535A (en) | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | Hydroxylamine substituted imidazo ring compounds |
EP1685129A4 (en) | 2003-11-14 | 2008-10-22 | 3M Innovative Properties Co | Oxime substituted imidazo ring compounds |
WO2005051317A2 (en) | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8802853B2 (en) | 2003-12-29 | 2014-08-12 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
JP2007517044A (en) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinylsulfonamide |
WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
US7943609B2 (en) | 2004-12-30 | 2011-05-17 | 3M Innovative Proprerties Company | Chiral fused [1,2]imidazo[4,5-C] ring compounds |
WO2006083440A2 (en) | 2004-12-30 | 2006-08-10 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
CA2597092A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
EP1846405A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
JP2008535832A (en) | 2005-04-01 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Pyrazolopyridine-1,4-diamine and analogs thereof |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1545597B1 (en) * | 2002-08-15 | 2010-11-17 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
EP2572714A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
JP2006517974A (en) * | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Methods and compositions for IRM compounds and Toll-like receptor 8 |
-
2006
- 2006-12-28 WO PCT/US2006/049431 patent/WO2007079146A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106474143A (en) * | 2015-08-26 | 2017-03-08 | 长春华普生物技术有限公司 | Toll-like receptor TLR7 and TLR9 inhibition oligonucleotides are preparing for treating the application in terms of the medicine of B cell lymphoma |
Also Published As
Publication number | Publication date |
---|---|
WO2007079146A1 (en) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007079146A8 (en) | Treatment for non-hodgkin's lymphoma | |
WO2007079171A3 (en) | Treatment for hodgkin's lymphoma | |
WO2007079202A3 (en) | Treatment for acute lymhoblastic leukemia | |
WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
WO2007079169A3 (en) | Treatment for acute myeloid leukemia | |
WO2006113942A3 (en) | Method of inhibiting cathepsin activity | |
WO2006078463A3 (en) | Method for treating cardiovascular disease | |
PL381247A1 (en) | Heterocyclical condensed derivative, the medical composition containing it as well as its treatment application | |
WO2005027839A3 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
WO2007140002A3 (en) | Method for treating non-hodgkin's lymphoma | |
WO2003057698A3 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
WO2007137071A3 (en) | Compositions of r(+) and s(-) pramipexole and methods of using the same | |
WO2005074607A3 (en) | Method of treating hemolytic disease | |
HK1084037A1 (en) | Medicament for treating severe heart failure | |
WO2005094785A3 (en) | Compositions capable of facilitating penetration across a biological barrier | |
BRPI0717753A2 (en) | METHOD OF TREATING OR REDUCING THE RISK OF A DISEASE CAUSED BY PROTOZOAN AND, COMPOSITION. | |
WO2005107771A3 (en) | Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer | |
EP1579213A4 (en) | Method of diagnosis,treatment and useful agents for conditions characterised by modulation in the level of activin beta c | |
AP2246A (en) | Pesticidal composition and method for seed treatment. | |
WO2008011478A3 (en) | Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | |
WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
WO2006138372A3 (en) | Methods and reagents for the treatment of inflammatory disorders | |
PL1694354T3 (en) | Method for preventing and treating diabetes using neurturin | |
WO2008016640A3 (en) | Use of poloxamer for the prevention and/or treatment of heart failure | |
WO2006121995A3 (en) | Methods for treating nephrolithiasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06848245 Country of ref document: EP Kind code of ref document: A1 |